Pantoprazole sodium for injection



[ingredients]



The main ingredient of this product is pantoprazole sodium.



[indications] it is suitable for acute upper gastrointestinal bleeding caused by duodenal ulcer, gastric ulcer, acute gastric mucosal lesion and compound ulcer.



[package specification] 40mg (according to pantoprazole)



[usage and dosage]



Intravenous drip. 40mg once a day, 1-2 times a day. Before use, inject 10ml of special solvent into lyophilized powder vial. Add the dissolved solution into 100ml of 0.9% sodium chloride injection for intravenous drip after dilution. The intravenous drip time should be 15-30 minutes. This product must be used up within 3 hours after dissolution and dilution. It is forbidden to dissolve and dilute with other solvents or other drugs.



[adverse reactions]



Occasionally, dizziness, insomnia, drowsiness, nausea, diarrhea, constipation, rash and muscle pain were observed. When used in large doses, arrhythmia, elevated transaminase, changes in renal function and neutropenia may occur.



[taboo]



It is forbidden for allergic patients; it is forbidden for pregnant and lactating women.



[precautions]



1. This product has a strong inhibitory effect on gastric acid secretion for a long time, so it is not suitable to take other antacids or antacids at the same time. In order to prevent excessive acid suppression, it is not recommended to use large dose for a long time in general peptic ulcer diseases (except Zhuo AI syndrome). 2. There is no need to adjust the dosage for patients with renal function impairment, and the dosage should be reduced for patients with liver function impairment. 3. In the treatment of gastric ulcer, gastric cancer should be excluded before using this product, so as not to delay the diagnosis and treatment. 4. In animal experiments, after long-term and large-scale use of this product, hypergastrinemia, secondary enlargement of gastric ECL cells and occurrence of benign tumors were observed. This change can also occur after application of other acid inhibitors and subtotal gastrectomy.



[medication for pregnant women]



It is forbidden for pregnant and lactating women.



[medication for children]



There is no experience of intravenous application of this product in children.



[medication for the elderly]



There is no need to adjust the dosage for the elderly.



[pharmacological action]



Pantoprazole, as a proton pump inhibitor, inhibits the last step of gastric acid production by covalently binding with two sites of H + - K + ATPase system of gastric parietal cells. This effect was dose-dependent and inhibited gastric acid secretion in both basal and stimulated states. The combination of this product with H + - K + ATPase can cause its anti gastric acid secretion effect to last more than 24 hours